Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2007 Nov 30;3(11):e214. doi: 10.1371/journal.pgen.0030214

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

PMC Copyright notice

(A) The RRP1B signature was highly predictive of overall survival in the Dutch Rosetta dataset, with the cumulative proportion survival being estimated to be 72% versus 34% for the good and poor prognosis RRP1B signatures, respectively (RRP1B signature HR = 3.28, 95% CI = 2.11–5.11). (B) Indeed, it appears that the RRP1B signature possesses a similar ability to predict survival in this dataset than the 70-gene signature described by van't Veer et al. [10]. Specifically, the survival for the good and poor prognosis 70-gene signatures were estimated to be 73% versus 47%, respectively (70 gene signature HR = 4.49, 95% CI = 2.65–7.61). (C) To stratify patients more adequately based upon their disease characteristics, RRP1B signature gene expression was examined with respect to tumor LN and ER status. Overall survival in the Dutch Rosetta patients with negative LNs was 79% versus 30% for the good and poor prognosis RRP1B signatures, respectively (HR = 4.34, 95% CI = 2.36–7.99). (D) Similarly, the RRP1B signature could sub-stratify patients with positive LNs into good and poor prognosis groups, with survivals being 65% versus 37%, respectively (HR = 2.38, 95% CI = 1.22–4.62). (E) A similar stratification effect by tumor RRP1B signature gene expression was observed in patients with ER positive tumors, with an overall survival in patients with ER positive tumors being 72% versus 50% for the good and poor prognosis RRP1B signatures, respectively (HR = 2.36, 95% CI = 1.17–4.77). (F) However, it did not prove possible to stratify patients with ER negative tumors based upon their RRP1B expression signature. This likely reflects the lack of individuals with this disease subtype in this cohort.